Trial in Progress: CA209-9Y8 phase 2 trial of tumor treating fields (TTFs), nivolumab plus/minus ipilimumab for bevacizumab-naïve, recurrent glioblastoma

Yazmin Odia

Trial in Progress: CA209-9Y8 phase 2 trial of tumor treating fields (TTFs), nivolumab plus/minus ipilimumab for bevacizumab-naïve, recurrent glioblastoma

Research output: Contribution to conference › Presentation

Original language	American English
State	Published - Nov 2019
Event	Society for NeuroOncology (SNO) 24th Annual Meeting and Education Day - Phoenix, AZ Duration: Nov 1 2019 → …

Conference

Conference	Society for NeuroOncology (SNO) 24th Annual Meeting and Education Day
Period	11/1/19 → …

Disciplines

Medicine and Health Sciences
Neoplasms
Neurology
Oncology

Cite this

@conference{323c700b1f164464b3ea35d49cb514fe,

title = "Trial in Progress: CA209-9Y8 phase 2 trial of tumor treating fields (TTFs), nivolumab plus/minus ipilimumab for bevacizumab-na{\"i}ve, recurrent glioblastoma",

author = "Yazmin Odia",

year = "2019",

month = nov,

language = "American English",

note = "Society for NeuroOncology (SNO) 24th Annual Meeting and Education Day ; Conference date: 01-11-2019",

}

TY - CONF

T1 - Trial in Progress: CA209-9Y8 phase 2 trial of tumor treating fields (TTFs), nivolumab plus/minus ipilimumab for bevacizumab-naïve, recurrent glioblastoma

AU - Odia, Yazmin

PY - 2019/11

Y1 - 2019/11

UR - https://academic.oup.com/neuro-oncology/article-abstract/21/Supplement_6/vi3/5619880?redirectedFrom=fulltext

M3 - Presentation

T2 - Society for NeuroOncology (SNO) 24th Annual Meeting and Education Day

Y2 - 1 November 2019

ER -

Trial in Progress: CA209-9Y8 phase 2 trial of tumor treating fields (TTFs), nivolumab plus/minus ipilimumab for bevacizumab-naïve, recurrent glioblastoma

Conference

Disciplines

Other files and links

Cite this